Horizon Therapeutics Plc

-0.26 (-0.26%)
5:13:03 PM EDT: $100.09 +0.42 (+0.42%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)22.79B
Current PE61.27
Forward PE 19.47
2yr Forward PE 15.72
See more stats
Estimates Current Quarter
Revenue$928.16 Million
Adjusted EPS$1.00
See more estimates
10-Day MA$100.57
50-Day MA$107.45
200-Day MA$93.64
See more pivots

Horizon Therapeutics Plc Stock, NASDAQ:HZNP

70 St. Stephen's Green, 1 Burlington Road, Dublin, Dublin 4
United States of America
Phone: +353.1.772.2100
Number of Employees: 2115


Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.